A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Exclusion Criteria

• •Prior use of any monoclonal antibody before study treatment
• •Treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent within 4 weeks of study treatment
• •Completion of autologous stem cell transplant within 6 months prior to study treatment
• •Prior allogeneic stem cell transplant
• •History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
• •Evidence of significant, uncontrolled concomitant diseases, including significant cardiovascular disease or pulmonary disease
• •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at screening or any recent major episode of infection requiring treatment with IV antibiotics or hospitalization prior to study treatment
• •Recent major surgery (prior to study treatment), other than for diagnosis
• •Presence of positive test results for Hepatitis B or Hepatitis C
• •Known history of HIV seropositive status
• •Women who are pregnant or lactating
• •Childbearing potential without agreement to use effective form of contraception for the duration of the study